These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11363091)

  • 1. Highlights of the Eighth European Cancer Conference.
    Prescott LM
    J Int Assoc Physicians AIDS Care; 1995 Dec; 1(11):34-5. PubMed ID: 11363091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
    Marcu LG
    Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
    Bourhis J; Blanchard P; Maillard E; Brizel DM; Movsas B; Buentzel J; Langendijk JA; Komaki R; Swan Leong S; Levendag P; Pignon JP
    J Clin Oncol; 2011 Jun; 29(18):2590-7. PubMed ID: 21576630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes in combined-modality therapy for solid tumors.
    Choy H
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):23-38. PubMed ID: 10550824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapy of solid tumors: pharmacologic activity or effectiveness?].
    Longo F; Mansueto G
    Tumori; 1999; 85(6):A26-33. PubMed ID: 10774584
    [No Abstract]   [Full Text] [Related]  

  • 7. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine.
    Braaksma M; van Agthoven M; Nijdam W; Uyl-de Groot C; Levendag P
    Eur J Cancer; 2005 Sep; 41(14):2102-11. PubMed ID: 16140526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Established and emerging uses of cytoprotection in head and neck cancer.
    Rosenthal DI
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):129-30. PubMed ID: 16490868
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential for use of amifostine in cervical cancer.
    Small W
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine.
    Chao KS; Ozyigit G; Thorsdad WL
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):101-8. PubMed ID: 14727250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of amifostine as a radioprotector.
    Wasserman TH; Brizel DM
    Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoradiotherapy for head and neck cancer: 'local' side effects are actually systemic.
    J Support Oncol; 2006 Feb; 4(2):88. PubMed ID: 16499131
    [No Abstract]   [Full Text] [Related]  

  • 16. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amifostine and curative intent chemoradiation for compromised cancer patients.
    Nguyen NP; Levinson B; Dutta S; Karlsson U; Kelly KC; Dowell J; Ludin A; Sallah S
    Anticancer Res; 2003; 23(2C):1649-56. PubMed ID: 12820436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new administration schedule for amifostine as a radioprotector in cancer therapy.
    Wagner W; Radmard A; Schönekaes KG
    Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine.
    Mell LK; Movsas B
    Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1341-50. PubMed ID: 18798703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.